Pfizer to Push Back Its COVID-19 Vaccine for Babies and Toddlers

After finding two doses don’t offer enough protection, Pfizer and BioNTech are now testing three doses for the youngest age group.
save article
profile picture of Nehal Aggarwal
Published December 17, 2021
Hero Image
Image: Getty Images

Pfizer and BioNTech are pushing back when they expect to have a vaccine for babies and toddlers.

The companies said that during a routine review they found the lower, 3-microgram dose they had been using during trials seems safe, but doesn’t offer enough protection for the youngest age group (0 to 5 years old). Instead of increasing the dosage, the companies are now testing three doses for its 3-microgram COVID-19 vaccine in kids aged 6 months to 5 years old. According to a statement released by the companies on December 17, the third dose will be given at least two months after the second dose.

“If the three-dose study is successful, Pfizer and BioNTech expect to submit data to regulators to support an Emergency Use Authorization (EUA) for children 6 months to under 5 years of age in the first half of 2022,” the statement says. They will also test a third dose of 10 micrograms in kids aged 5 to 11, as well as a third dose of 10 micrograms or 30 micrograms in study participants aged 12 to 17.

To learn more about the new timeline and read the full statement, visit

save article

Next on Your Reading List

Article removed.
Name added. View Your List